european urology 52 (2007)
|
|
- Della Farmer
- 5 years ago
- Views:
Transcription
1 european urology 52 (2007) available at journal homepage: Kidney Cancer Platelet Count and Preoperative Haemoglobin Do Not Significantly Increase the Performance of Established Predictors of Renal Cell Carcinoma-Specific Mortality Pierre I. Karakiewicz a, *,1, Quoc-Dien Trinh a,1, John S. Lam b, Jacques Tostain c, Allan J. Pantuck b, Arie S. Belldegrun b, Jean-Jacques Patard d a Cancer Prognostics and Health Outcome Unit, University of Montreal Health Center, Montreal, Quebec, Canada b Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, California, United States c Department of Urology, North Hospital, CHU of Saint-Etienne, Saint-Etienne, France d Department of Urology, Rennes University Hospital, Rennes, France Article info Article history: Accepted March 15, 2007 Published online ahead of print on March 28, 2007 Keywords: Renal cell carcinoma Survival Anaemia Thrombocytosis Prognostic Abstract Objective: Anaemia and/or thrombocytosis were identified as independent predictors of poor survival in renal cell carcinoma (RCC). We tested the extent to which these markers worsen the prognosis in these patients. Methods: Analyses targeted 1828 patients with renal cell carcinoma. Univariable, multivariable, and predictive accuracy analyses addressed RCC-specific mortality (RCC-SM). Results: In univariable and multivariable analyses, both platelet count and preoperative haemoglobin level were statistically significant predictors of RCC-SM. However, neither platelet count nor preoperative haemoglobin level increased the combined multivariable accuracy of established RCC-SM (predictive accuracy gain = 0.3%) predictors. Conclusions: Patients who present with severe anaemia or elevated platelets are at no higher risk of RCC-SM than that related to their stage, grade, histologic subtype, and Eastern Cooperative Oncology Group- Performance Status. # 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Corresponding author. Cancer Prognostics and Health Outcome Unit, University of Montreal Health Center (CHUM), 1058, Rue St-Denis, Montreal, Quebec, Canada, H2X 3J4. Tel ; Fax: address: pierre.karakiewicz@umontreal.ca (P.I. Karakiewicz). 1 Equally contributing authors. 1. Introduction Renal cell carcinoma (RCC) accounts for 3% of cancers in adults as well as 85% of all primary malignant kidney tumours [1]. Unfortunately, nearly 25% of contemporary patients are diagnosed with either nodal or distant metastases and have poor prognosis [2,3]. Stage at presentation represents a /$ see back matter # 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eururo
2 european urology 52 (2007) valuable prognostic variable and is closely associated with renal cell carcinoma-specific mortality (RCC-SM). Nonetheless, some patients with localized RCC succumb to their disease. Unfavourable histologic subtypes, such as collecting duct or sarcomatoid variants, account for worse survival. However, in other patients, obvious variables, such as grade, stage, and histology, cannot account for the unexpectedly poor survival. Patients demonstrating systemic disease manifestations, such as anaemia and/or thrombocytosis, may represent a subgroup with particularly poor prognosis. Indeed, thrombocytosis was shown to portend a particularly poor survival in five contemporary RCC cohorts [4 8]. Anaemia was associated with an equally poor prognosis [9 12]. Despite this evidence, the added value of these markers in prediction of RCC-SM has never been tested. Thus, it is presently unknown whether anaemia or thrombocytosis should be routinely considered when survival is considered. On the basis of these considerations, we tested the ability of thrombocytosis and anaemia to improve the predictive accuracy of established RCC-SM predictors. If thrombocytosis and/or anaemia prove to add to the prognostic ability of established markers, then they should be added to standard prognostic variables. If not, then it can be safely assumed that patients with thrombocytosis or anaemia are at no different risk than that caused by the established risk factors. 2. Material and methods 2.1. Patient population Data were retrieved from three combined institutional review board-approved institutional databases, which totalled 1828 patients treated with partial or radical nephrectomy between 1984 and 2001 (Table 1) Clinical and pathologic evaluation Platelet count and preoperative haemoglobin level were available for all patients in our cohort. Tumours were classified according to the 2002 TNM staging system and the Fuhrman grade. Tumour size was based on pathologic specimens and was defined as the greatest diameter in centimetres. Prior to study inclusion, histologic subtypes were stratified according to the 2002 American Joint Committee on Cancer/Union Internationale Contre le Cancer classifications [13]. Symptoms were prospectively recorded at each of the participating institutions. The symptom classification was defined as previously described [14]. Patients were staged preoperatively with computed tomography (CT) of the abdomen and pelvis, chest CT or chest x-ray, serum electrolytes, and liver function tests. Presence of nodal metastases was defined according to lymphadenectomy findings. In all cases a hilar lymphadenectomy was performed, which included all lymph nodes on the ipsilateral side of the great vessels. In select cases, on the basis of surgeon preference, more extensive lymphadenectomies that included inter-aorto-caval lymph nodes were performed. In all cases presence of nodal metastases was confirmed pathologically. Presence of distant metastases was confirmed on the basis of radiographic and/or histologic findings. Follow-up consisted of one postoperative baseline visit and was then performed every 6 mo for a minimum of 2 yr. Subsequently, minimum follow-up consisted of annual visits. At each visit, a CT of the chest or a chest x-ray accompanied a CT of the abdomen. The cause of death was either obtained from the medical chart and recorded prospectively or was obtained from the death certificate in a retrospective fashion. RCC-specific mortality included deaths that were directly attributable to kidney cancer Statistical analyses Kaplan-Meier plots were used to graphically illustrate the RCC-specific survival (RCC-SS) for the entire cohort, as well as the effect of dichotomised platelet count and haemoglobin level on RCC-SS. Univariable and multivariable Cox regression models addressed the effect of all predictors on RCC-SM. These predictors included age, TNM stages, tumour size, Fuhrman grade, histologic type, Eastern Cooperative Oncology Group-Performance Status (ECOG-PS), as well as the platelet count and haemoglobin level [15 18]. Univariable predictive accuracy was determined for each predictor, including platelet count and haemoglobin level. For platelet count and haemoglobin level, we tested whether one or several cut-offs could result in an increase in predictive accuracy. We also included the previously suggested platelet count cut-off of per litre in univariable as well as all multivariable analyses [4]. Anaemia was defined as preoperative haemoglobin level 11.9 g/dl. In all analyses, predictive accuracy was defined as the ability of the model to discriminate between those who succumbed to RCC from those who did not. Predictive accuracy was expressed as a percentage with the use of the Harrell s concordance index, in which 50% represents a flip of a coin and 100% represents ideal prediction. The combined predictive accuracy of all standard RCC-SM predictors was quantified in the base multivariable model, which included neither the platelet count nor the haemoglobin level. The change in the multivariable predictive accuracy related to the inclusion of either one or both variables was then established in extended models. The effect of inclusion of either continuously coded or categorized platelet count and haemoglobin level was tested. To reduce overfit bias, all univariable and multivariable models were subjected to 200 bootstrap resamples. All analyses were repeated after stratification of the cohort into three subcohorts (Table 1): localized RCC (T 1 2 N 0 M 0 ), locally advanced RCC (T 3 N 0 1 M 0 ), and metastatic RCC (T any N any M 1 ). The intent of these subanalyses was to explore the potential contribution of platelet count and haemoglobin levelling patients with significantly different
3 1430 european urology 52 (2007) Table 1 Descriptive characteristics of 1828 patients treated with nephrectomy for renal cell carcinoma Variable Overall cohort Localized RCC (T1 2N0M0) Locally advanced RCC (T3N0 1M0) Metastatic RCC (TanyNanyM1) Total 1828 (100.0%) 827 (100.0%) 449 (100.0%) 508 (100.0%) Centre Rennes University Hospital, Rennes, France 483 (26.4%) 230 (27.8%) 147 (32.7%) 92 (18.1%) CHU of Saint-Etienne, Saint-Etienne, France 431 (23.6%) 195 (23.6%) 165 (36.7%) 64 (12.6%) UCLA 914 (50.0%) 402 (48.6%) 137 (30.5%) 352 (69.3%) Age (yr) Mean (median) 61.4 (63.0) 61.0 (63.0) 63.3 (65.0) 60.1 (61.0) Range Gender F 617 (33.8%) 302 (36.5%) 157 (35.0%) 141 (27.8%) M 1211 (66.2%) 525 (63.5%) 292 (65.0%) 367 (72.2%) T stage T (40.2%) 656 (79.3%) 72 (14.2%) T (12.8%) 171 (20.7%) 55 (10.8%) T (43.9%) 449 (100.0%) 341 (67.1%) T 4 56 (3.1%) 40 (7.9%) Tumor size (cm) Mean (median) 7.1 (6.4) 5.2 (4.5) 8.1 (8.0) 8.9 (8.5) Range Histologic type Conventional clear cell 1538 (84.1%) 666 (80.5%) 392 (87.3%) 448 (88.2%) Papillary 196 (10.7%) 121 (14.6%) 37 (8.2%) 32 (6.3%) Chromophobe 66 (3.6%) 38 (4.6%) 18 (4.0%) 8 (1.6%) Collecting duct and unclassified 28 (1.5%) 2 (0.2%) 2 (0.4%) 20 (3.9%) Fuhrman grade I 210 (11.5%) 175 (21.2%) 26 (5.8%) 8 (1.6%) II 747 (40.9%) 430 (52.0%) 165 (36.7%) 145 (28.5%) III 634 (34.7%) 201 (24.3%) 193 (43.0%) 219 (43.1%) IV 237 (13.0%) 21 (2.5%) 65 (14.5%) 136 (26.8%) Presence of nodal metastases (N 1 2 ) 249 (13.6%) 60 (13.4%) 156 (30.7%) N (9.0%) 60 (13.4%) 93 (18.3%) N 2 84 (4.6%) 63 (12.4%) Presence of distant metastases (M 1 ) 508 (27.8%) 508 (100.0%) ECOG-PS (42.8%) 197 (23.8%) 193 (43.0%) 364 (71.7%) Platelet count (10 9 /l) Mean (median) (271.0) (253.0) (271.0) (310.0) Range Platelet count (10 9 /l) (dichotomized) < (90.6%) 793 (95.9%) 406 (90.4%) 424 (83.5%) (9.4%) 34 (4.1%) 43 (9.6%) 84 (16.5%) Platelet count (10 9 /l) (most informative cut-offs) (27.3%) 274 (33.1%) 127 (28.3%) 90 (17.7%) (33.5%) 308 (37.2%) 148 (33.0%) 148 (29.1%) (17.1%) 134 (16.2%) 67 (14.9%) 103 (20.3%) (22.1%) 111 (13.4%) 107 (23.8%) 167 (32.9%) Preoperative haemoglobin (g/dl) Mean (median) 13.0 (13.1) 13.5 (13.7) 12.8 (12.9) 12.4 (12.4) Range Preoperative haemoglobin (g/dl) (dichotomized) < (29.3%) 149 (18.0%) 149 (33.2%) 217 (42.7%) (70.7%) 678 (82.0%) 300 (66.8%) 291 (57.3%) Preoperative haemoglobin (g/dl) (most informative cut-offs) (15.4%) 67 (8.1%) 79 (17.6%) 122 (24.0%) (13.9%) 82 (9.9%) 70 (15.6%) 95 (18.7%) (20.7%) 167 (20.2%) 90 (20.0%) 113 (22.2%) (17.5%) 171 (20.7%) 67 (14.9%) 75 (14.8%)
4 european urology 52 (2007) Table 1 (Continued ) Variable Overall cohort Localized RCC (T1 2N0M0) Locally advanced RCC (T3N0 1M0) Metastatic RCC (TanyNanyM1) (10.2%) 107 (12.9%) 43 (9.6%) 34 (6.7%) (21.2%) 226 (27.3%) 94 (20.9%) 63 (12.4%) (1.1%) 7 (0.8%) 6 (1.3%) 6 (1.2%) RCC-specific mortality 489 (26.8%) 54 (6.5%) 119 (26.5%) 296 (58.3%) Follow-up (yr) Mean (median) 3.6 (2.1) 4.4 (3.3) 4.3 (2.9) 1.6 (0.8) Range Time to death for those that died (yr) Mean (median) 2.0 (1.2) 3.9 (3.5) 2.9 (2.0) 1.4 (0.8) Range Actuarial median (mean) survival (yr) 13.6 (17.3) 18.9 (not reached) 13.4 (14.7) 3.4 (1.7) RCC = renal cell carcinoma; UCLA = University of California, Los Angeles; ECOG-PS = Eastern Cooperative Oncology Group-Performance Status. prognostic profiles. All statistical tests were performed with S-PLUS Professional, version 1 (MathSoft Inc, Seattle, WA, USA). Moreover, all tests were two-sided with a significance level set at Results Patient characteristics are shown in Table 1. The majority (n = 1211, 66.2%) were men whose age ranged from 10 to 94 yr (mean: 61.4; median: 63.0). Of 1828 RCC patients treated with nephrectomy, pt1, pt2, pt3, and pt4 respectively accounted for 710 (38.8%), 259 (14.2%), 803 (43.9%), and 56 (3.1%) cases. The mean tumour size was 7.1 cm (range: ; median: 6.4 cm). Clear-cell histology was present in 1583 cases (84.1%). Sarcomatoid and unclassified RCC tumours accounted for 1.5% of all cases (n = 28). Fuhrman II (40.9%) and III (34.7%) represented the most frequent tumour grades. Node-positive disease was diagnosed in 13.6% of cases, whilst 27.8% had systemic metastases. ECOG- PS 1 was present in 42.8% of patients. Platelet count ranged from 44 to per litre. Of the entire cohort, 171 patients (9.4%) demonstrated a platelet count per litre [4]. The mean and median preoperative haemoglobin levels were respectively 13.0 and 13.1 g/dl (range: ). Most patients (n = 1292, 70.7%) had a preoperative haemoglobin level 11.9 g/dl, whilst 29.3% were anaemic at the time of diagnosis. The overall follow-up time ranged from 0.1 to 22.8 yr (mean: 3.6; median: 2.1). Of all patients, 489 (26.8%) died of RCC, and an additional 149 (8.1%) died of other causes. For those who died of RCC, the mean and median times to RCC-specific death were respectively 2.0 and 1.2 yr (range: ). For all patients at risk, the actuarial mean and median survival values were respectively 17.3 and 13.6 yr. Fig. 1 shows RCC-SS for the entire cohort, whilst Fig. 2 shows the survival dichotomised according to the previously suggested platelet count ( per litre). The mean and median values for survival of patients with platelet count per litre were 5.6 and 2.4 yr. Fig. 3 shows the survival dichotomised according to the previously suggested preoperative haemoglobin level (11.9 g/dl). The mean and median values for survival of patients with preoperative haemoglobin level <11.9 g/dl were 10.0 and 4.7 yr. Table 2 shows the univariable analyses addressing RCC-SM, for which tumour size, TNM stages, ECOG-PS, histologic subtype, platelet count, and preoperative haemoglobin level represented statistically significant predictors of RCC-SM. When univariable predictive accuracy was analysed, M stage represented the most informative predictor of RCC-SM (74.3%), followed by T stage (71.4%), Fuhrman grade (70.5%), tumour size (70.2%), and Fig. 1 Renal cell carcinoma-specific survival in the study cohort of 1828 patients treated with nephrectomy.
5 1432 european urology 52 (2007) Fig. 2 Renal cell carcinoma-specific survival stratified according to dichotomously coded platelet count (cut-off of 450 T 10 9 per litre). ECOG-PS (68.6%), with 50% accuracy representing a random event. The accuracy of platelet count ranged from 55.8% to 65.2%, depending on its coding. The lowest predictive accuracy was recorded when the previously reported cut-off of per litre was used. Continuously coded platelet count yielded 65.2% predictive accuracy; when the most informative cut-offs were identified, predictive accuracy was 65.2%. Preoperative haemoglobin level was 65.2% accurate in predicting RCC-SM; its value increased to 65.3% when the most informative cut-offs were identified. Table 2 also shows the multivariable analyses and the predictive accuracy of multivariable models. All variables achieved independent predictor status in the base model (all p values 0.05). The base multivariable model, which excluded platelet count and preoperative haemoglobin, was 85.3% accurate in predicting RCC-SM. Inclusion of the platelet count, using its most informative categoric coding, Fig. 3 Renal cell carcinoma-specific survival stratified according to dichotomously coded preoperative haemoglobin (cut-off of 11.9 g/dl).
6 european urology 52 (2007) Table 2 Univariable and multivariable analyses predicting renal cell carcinoma-specific mortality Predictor Univariable Multivariable Rate ratio; p value Predictive accuracy Baseline Model 1 Model 2 Model 3 Rate ratio; p value Rate ratio; p value Rate ratio; p value Rate ratio; p value Age 1.0; % 1.0; ; ; ; 0.01 Tumour size 1.2; < % 1.0; ; ; ; 0.1 T stage ; < % ; <0.001 ; <0.001 ; <0.001 ; <0.001 T 2 vs. T 1 4.0; < ; ; ; ; T 3 vs. T 1 6.7; < ; < ; < ; < ; <0.001 T 4 vs. T ; < ; < ; < ; < ; <0.001 Presence of nodal metastases (N 1 2 ) ; < % ; <0.001 ; <0.001 ; <0.001 ; <0.001 N 1 vs. N 0 4.8; < ; < ; < ; < ; <0.001 N 2 vs. N 0 4.2; < ; ; ; ; 0.4 Presence of distant metastases (M 1 ) 8.5; < % 4.1; < ; < ; < ; <0.001 ECOG-PS (0 vs. 1) 4.1; < % 1.9; < ; < ; < ; <0.001 Fuhrman grade ; < % ; <0.001 ; <0.001 ; <0.001 ; <0.001 II vs. I 4.1; < ; ; ; ; 0.02 III vs. I 8.7; < ; ; ; ; IV vs. I 22.7; < ; < ; < ; < ; <0.001 Histologic type ; < % ; ; ; <0.001 ; Papillary vs. clear 0.6; ; ; ; ; 0.7 Chromophobe vs. clear 0.5; ; ; ; ; 0.9 Sarcomatoid and undifferentiated vs. clear 9.6; < ; < ; ; < ; <0.001 Platelet count (10 9 /l) (continuously coded) 1.0; < % Platelet count (450 vs. < /l) 2.8; < % Platelet count (10 9 /l) (most informative) ; < % ; <0.001 ; <0.001 > vs ; ; ; 0.02 > vs ; < ; ; > vs ; < ; < ; <0.001 Preoperative haemoglobin (g/dl) (continously coded) 0.8; < % Preoperative haemoglobin (g/dl) ; < % ; 0.02 ; 0.2 > vs ; ; ; 0.1 > vs ; < ; ; 0.1 > vs ; < ; ; 0.2 > vs ; < ; ; 0.02 > vs ; < ; ; 0.3 > vs ; ; ; 0.8 Predictive accuracy 85.3% 85.6% 85.4% 85.6% ECOG-PS = Eastern Cooperative Oncology Group-Performance Status. Model 1: platelet count coded using most informative cut-offs. Model 2: preoperative haemoglobin coded using most informative cut-offs. Model 3: platelet count and preoperative haemoglobin coded using most informative cut-offs. The rate ratio indicates the increase in the rate of renal cell carcinoma-specific mortality related to each predictor. resulted in predictive accuracy of 85.6% (gain of 0.3%). When the most informative variant of preoperative haemoglobin level was added to the base model, predictive accuracy was 85.4% (gain of 0.1% from base). Finally, when both variables were added by using their most informative univariable coding, predictive accuracy reached 85.6% (gain of 0.3%). The three subgroup analyses showed no benefit related to the addition of platelet count or haemoglobin level or both variables, as evidenced by predictive accuracy gains that ranged from 0.6 to +1.2% ( p 0.5). 4. Discussion Several studies have shown that anaemia and thrombocytosis correlated with poor outcomes in patients with RCC [4 12]. Because of their potential value and the availability of platelet count and
7 1434 european urology 52 (2007) preoperative haemoglobin level for invariably all patients with RCC, we hypothesized that these variables could improve the prognostic ability of other established markers. To address this hypothesis, we used the most stringent methodologic criteria suggested by Kattan [19], in which, besides demonstrating the independent predictor status of a novel marker, the candidate marker should enhance the accuracy of established predictors. We added this methodology to the standard univariable and multivariable regression analyses that all previous studies relied on. Our Kaplan-Meier analyses demonstrated that platelet count as well as preoperative haemoglobin level can accurately stratify between those with poor prognosis and those with better prognosis (both log-rank p 0.001). Moreover, univariable analyses predicting RCC-SM also confirmed that both platelet count and preoperative haemoglobin level represented statistically significant predictors ( p < 0.001). In univariable predictive accuracy tests, accuracy of a platelet count coded as a dichotomous variable (cut-off of per litre), continuously coded, or coded using its most informative categoric coding (Table 1) was respectively 55.8%, 65.2%, or 65.2%. Similarly, accuracy value of preoperative haemoglobin level coded as a continuous variable or using its most informative categoric coding (Table 1) was respectively 65.2% or 65.3%. In multivariable analyses, platelet count ( p < 0.001) and preoperative haemoglobin level ( p = 0.02), in their most informative formats, achieved independent predictor status. However, little change in predictive accuracy was recorded when platelet count and preoperative haemoglobin level were added to the base model that contained all standard predictors (age, tumour size, TNM stage, ECOG-PS, Fuhrman grade, and histologic subtype). Specifically, when the most informative coding of the platelet count was added to the base model, predictive accuracy increased by 0.3% (from 85.3% to 85.6%). Similarly, when the base model was complemented with the most informative coding of preoperative haemoglobin, predictive accuracy increased only by 0.1% (from 85.3% to 85.4%). When both platelet count and preoperative haemoglobin level were added, the predictive accuracy increased by 0.3%, from 85.3% to 85.6%. From a practical perspective, a gain of 0.3% corresponds to correctly classifying 3 additional patients out of 1000, relative to a prognostic scheme that does not include these two variables. These predictive accuracy changes were not statistically significant. Moreover, when we repeated our analyses in the three subgroups (localized vs. locally advanced vs. metastatic), we found no benefit from adding platelet count or haemoglobin level or both variables. This finding implies that no specific patient subgroup appears to benefit from the consideration of these variables. These observations emphasize that anaemia and thrombocytosis may represent statistically significant predictors of RCC-SM in univariable and multivariable models. However, their addition to established variables does not improve the ability to predict RCC-SM. These findings indicate that anaemia and thrombocytosis do not fulfil the characteristics of informative markers of RCC-SM. From a clinical perspective, our results demonstrate that patients who present with thrombocytosis and/or anaemia do not have worse prognosis than their counterparts who do not exhibit these apparently unfavourable characteristics, as long as the effect of TNM stage, histology, tumour grade, and ECOG-PS is considered. In consequence, treatment decisions, such as nephrectomy or delivery of systemic therapy should not be based on the consideration of either thrombocytosis or anaemia. This finding is important since many novel markers may be aggressively promoted on the basis of their independent predictor status. To address the issue of potentially exaggerated effect of such candidate markers, Kattan [19] recommends that a novel marker not only should be judged according to its multivariable statistical significance but also should increase the combined predictive accuracy of established base predictors. Consequently, a novel marker should be judged by its added value. Our work has indicated that neither thrombocytosis nor anaemia add any value to established predictors in a large cohort of 1828 patients. Our findings are consistent with previous analyses of independent predictor status and predictive accuracy, in which independent predictor status did not invariably translate into increase of predictive accuracy [17,20,21]. Therefore, it may be postulated that independent predictor status of several predictors might have been overrated, as was the case in this analysis. In the case of thrombocytosis, several investigators demonstrated that it represents an independent predictor of RCC-SM. These include Symbas et al [7] (n = 259), O Keefe et al [5] (n = 204), Inoue et al [6] (n = 196), Gogus et al [8] (n = 151), and Bensalah et al [4] (n = 804). Similarly, a number of studies have shown that anaemia represents a significant predictor of RCC-SM. These include Citterio et al [10] (n = 109) as well as Motzer et al in 1999 [12] (n = 670) and 2004 [11] (n = 251), who respectively assessed the effect of anaemia prior to nephrectomy and in the
8 european urology 52 (2007) metastatic setting, where nephrectomy was not always performed. Our overall analysis indicated that anaemia has no prognostic relevance. Moreover, our subgroup analyses, in which we assessed the prognostic relevance of anaemia in patients with localized, locally advanced, or finally metastatic RCC confirmed its lack of prognostic relevance in either of the subgroups. The discrepancy between our study and the previous reports, in which either thrombocytosis and/or anaemia represented key predictor variables, may be explained in several ways. First, none of the previous studies used the Kattan approach for testing of the added value of a novel marker. It is possible that, if this approach had been used, anaemia or thrombocytosis or both variables would not have been identified as prognostically relevant variables. Second, important differences exist between our study and, for example, that of Motzer et al [12], in which 670 patients with metastatic RCC were studied and anaemia represented one of the key prognostic variables. One of the main differences relates to the fact that only 65% of patients underwent a nephrectomy in Motzer et al s cohort versus 100% in our series. Thus, one third of Motzer et al s cohort had disease or ECOG-PS that did not allow for a nephrectomy. This important difference might have obliterated the prognostic relevance of anaemia in our cohort, whilst anaemia exerted a significant effect in Motzer et al s cohort. Finally, crucial differences between available predictor variables distinguish our study from others, such as that of Motzer et al [12]. In our series, TNM stages, tumour grade, histology, and ECOG-PS represented the strategic prognostic determinants. In Motzer et al s series, except for ECOG-PS, these variables were not universally available and could not be included in the final multivariable model (Motzer criteria). The recognition of this difference between our model and that of Motzer et al is crucial when the prognostic relevance of anaemia is interpreted and possibly extrapolated to a setting different from a surgical series. As we stated in our results, anaemia has no prognostic relevance when it is considered alongside stage, grade, histology, and ECOG-PS. However, this observation does not imply that anaemia has no bearing on prognosis when the Motzer criteria are used and when the effect of anaemia is considered with entirely different prognostic variables such as albumin, alkaline phosphatase, lactate dehydrogenase, and corrected calcium. These laboratory values certainly exert a different effect on prognosis than TNM stage, histology, and grade. Therefore, we wish to emphasize that the prognostic irrelevance of anaemia applies when it is considered with TNM stage, histology, tumour grade, and ECOG-PS. Conversely, anaemia may have an entirely different effect on prognosis when it is examined with variables that are part of the Motzer criteria. In the latter case, the effect of anaemia should not be discounted on the basis of the current report. Several other limitations may apply to our findings. Detailed information regarding adjuvant and/or salvage treatment regimens of some of our patients was not available. Some received adjuvant immunotherapy, whilst others received immunotherapy at relapse. Finally, some were treated with experimental chemotherapy, whilst others received only the best supportive care. It is unlikely that adjuvant or salvage therapies have contributed to a significantly longer survival, because the majority of historic regimens are associated with dismal effect on survival [22]. Nonetheless, our survival findings might have been contaminated by the effect of immunotherapy in some individuals. Moreover, we addressed only survival. Thrombocytosis and anaemia may have a stronger effect on RCC recurrence. Therefore, separate analyses are needed to elucidate the prognostic significance of these variables in recurrence prediction. Finally, our patients originated from Europe and the United States. Therefore, individuals of different ethnic or racial backgrounds may exhibit different characteristics with respect to the importance of thrombocytosis and anaemia. Despite these and other limitations, our data provide an important insight into RCC-SM of patients with high platelet counts or low preoperative haemoglobin levels. 5. Conclusions Our findings indicate that platelet count and preoperative haemoglobin level are statistically significant and independent predictors of poor RCC-SM. However, platelet count and preoperative haemoglobin level do not add to the predictive accuracy of established predictors of RCC-SM in multivariable analyses. Therefore, clinical decision making should not be affected by either platelet count or preoperative haemoglobin level when TNM stage, tumour histology, tumour grade, and ECOG- PS are known. Conflicts of interest The authors have nothing to disclose.
9 1436 european urology 52 (2007) References [1] Dhote R, Pellicer-Coeuret M, Thiounn N, et al. Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. BJU Int 2000;86:20 7. [2] Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166: [3] Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353: [4] Bensalah K, Leray E, Fergelot P, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 2006;175: [5] O Keefe SC, Marshall FF, Issa MM, et al. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol 2002;168: [6] Inoue K, Kohashikawa K, Suzuki S, et al. Prognostic significance of thrombocytosis in renal cell carcinoma patients. Int J Urol 2004;11: [7] Symbas NP, Townsend MF, El-Galley R, et al. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000;86: [8] Gogus C, Baltaci S, Filiz E, et al. Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 2004;63: [9] Yasunaga Y, Shin M, Miki T, et al. Prognostic factors of renal cell carcinoma: a multivariate analysis. J Surg Oncol 1998;68:11 8. [10] Citterio G, Bertuzzi A, Tresoldi M, et al. Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. Eur Urol 1997;31: [11] Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22: [12] Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17: [13] Greene FL, Page DL, Fleming ID, et al, editors. American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual. 6th ed. New York: Springer; [14] Patard J-J, Leray E, Rodriguez A, et al. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol 2003;44: [15] Taccoen X, Valeri A, Descotes J-L, et al. Renal cell carcinoma in adults 40 years old or less: young age is an independent prognostic factor for cancer-specific survival. Eur Urol 2007;51: [16] Ficarra V, Martignoni G, Galfano A, et al. Prognostic role of the histologic subtypes of renal cell carcinoma after slide revision. Eur Urol 2006;50:786 93, discussion [17] Karakiewicz PI, Lewinshtein DJ, Chun FK-H, et al. Tumor size improves the accuracy of TNM predictions in patients with renal cancer. Eur Urol 2006;50: [18] Lane BR, Kattan MW. Predicting outcomes in renal cell carcinoma. Curr Opin Urol 2005;15: [19] Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003;95: [20] Mallah KN, DiBlasio CJ, Rhee AC, et al. Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy. Cancer 2005;103: [21] Graefen M, Ohori M, Karakiewicz PI, et al. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol 2004;171: [22] Bleumer I, Oosterwijk E, De Mulder P, Mulders PFA. Immunotherapy for renal cell carcinoma. Eur Urol 2003;44: Editorial Comment on: Platelet Count and Preoperative Haemoglobin Do Not Significantly Increase the Performance of Established Predictors of Renal Cell Carcinoma-Specific Mortality Axel Bex The Netherlands Cancer Institute, Division of Surgical Oncology, Department of Urology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands a.bex@nki.nl Several attempts are underway to find a consensus for a unifying and universal model that can be used to predict prognosis and treatment outcome in the future for patients with renal cell carcinoma (RCC). In this regard, the article by Karakiewicz et al [1] adds valuable information to the discussion. Some of the established predictive factors are part of the Universal Integrated Staging System (UISS) score. In established metastatic RCC the TNM stage is less important with regard to T stage, which is why a metastatic UISS score has been validated with N1 and N2/M1 as a variable together with grade and Eastern Cooperative Oncology Group (ECOG) performance [2]. However, other metastatic risk assessment scores such as the Memorial Sloan-Kettering Cancer Center (MSKCC) score are widely used [3]. Though initially established from analysing patients who were treated with interferon-a, this score is now often applied to assess the risk of a metastatic patient prior to treatment. In France a similar, but slightly different score is used [4]. In the MSKCC score hemoglobin count is one of the five clinical parameters of Karnofsky, time from diagnosis to treatment, serum calcium, lactic dehydrogenase, and hemoglobin that predict survival with a low, intermediate, and poor risk. Thus, having a low hemoglobin and no other parameters (=1 risk factor) would put a patient with an otherwise low risk (0 risk factor)
10 european urology 52 (2007) and a survival of >29.6 mo in the intermediate-risk group with a survival of 13.8 mo. Low hemoglobin may therefore be responsible for a survival difference of a median of almost 16 mo. Karakiewicz et al [1] evaluated the added accuracy of hemoglobin in M1 and N2 patients without being able to demonstrate an increase. This may be a result of a different patient population, as they analysed preoperative hemoglobin values. Additionally, only 27.8% of their patients had distant metastases, whereas the MSKCC score was established in an entirely metastatic patient population. Again, this article underscores the need for a universal model. References [1] Karakiewicz PI, Trinh Q-D, Lam JS, et al. Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol 2007; 52: [2] Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004;22: [3] Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20: [4] Negrier S, Douilard JY, Gomez F, Lasset C, Chevreau C, Escudier B. Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group. Prog Urol 2002;12: DOI: /j.eururo DOI of original article: /j.eururo
PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CHEMOTHERAPY
Journal of IMAB ISSN: 1312-773X http://www.journal-imab-bg.org http://dx.doi.org/10.5272/jimab.2016221.1045 Journal of IMAB - Annual Proceeding (Scientific Papers) 2016, vol. 22, issue 1 PROGNOSTIC FACTORS
More informationPrognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?
european urology supplements 8 (2009) 478 482 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will
More informationTumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationPrognostic factors in localized renal cell cancer
Original Article PROGNOSTIC FACTORS IN LOCALIZED RENAL CELL CANCER KNIGHT and STADLER Prognostic factors in localized renal cell cancer David A. Knight and Walter M. Stadler Section of Hematology/Oncology,
More informationIs There a Need to Further Subclassify pt2 Renal Cell Cancers as Implemented by the Revised 7th TNM Version?
EUROPEAN UROLOGY 59 (2011) 258 263 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Is There a Need to Further Subclassify pt2 Renal Cell Cancers as Implemented
More informationCLINICAL INVESTIGATION of new agents and combination
Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma By Robert J. Motzer, Jennifer Bacik, Barbara A. Murphy, Paul Russo, and Madhu Mazumdar
More informationTyrosine Kinase Inhibitors in Clinical Practice: Case Reports
european urology supplements 7 (2008) 610 614 available at www.sciencedirect.com journal homepage: www.europeanurology.com Tyrosine Kinase Inhibitors in Clinical Practice: Case Reports Vincenzo Ficarra
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationUrinary Collecting System Invasion is an Independent Prognostic. Factor in Organ Confined Renal Cell Carcinomas.
Author manuscript, published in "Journal of Urology The 2009;182(3):854-9" DOI : 10.1016/j.juro.2009.05.017 Urinary Collecting System Invasion is an Independent Prognostic Factor in Organ Confined Renal
More informationSustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma
JOURNAL OF CASE REPORTS 2015;5(1):280-284 Sustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma Chanchal Goswami, Aditi Mandal B. P. Poddar Hospital & Medical Research
More informationZonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy
european urology 51 (2007) 949 955 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical
More informationCANCER UROLOGY VOL. 12. P. S. Borisov 1, M. I. Shkol nik 2, R. V. Orlova 3, P. A. Karlov 1 DOI: /
CANCER UROLOGY 3 6 VOL. The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study
More informationThe Changing Evolution of Renal Tumours: A Single Center Experience over atwo-decade Period
European Urology European Urology 45 (2004) 490 494 The Changing Evolution of Renal Tumours: A Single Center Experience over atwo-decade Period Jean-Jacques Patard a,*, Hicham Tazi a, Karim Bensalah a,
More informationThe Karakiewicz Nomogram Is the Most Useful Clinical Predictor for Survival Outcomes in Patients With Localized Renal Cell Carcinoma
The Karakiewicz Nomogram Is the Most Useful Clinical Predictor for Survival Outcomes in Patients With Localized Renal Cell Carcinoma Min-Han Tan, MBBS, MRCP 1,2,3 ; Huihua Li, PhD 4 ; Caroline Victoria
More informationIto et al. BMC Cancer 2012, 12:337
Ito et al. BMC Cancer 212, 12:337 RESEARCH ARTICLE Open Access C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationPrognostic Factors and Staging Systems for Renal Cell Carcinoma
european urology supplements 6 (2007) 623 629 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors and Staging Systems for Renal Cell Carcinoma Vincenzo Ficarra
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationSAMPLING OF POST NEPHRECTOMY CANCER CARE (5)
SAMPLING OF POST NEPHRECTOMY CANCER CARE (5) Universally recognized post-nephrectomy cancer treatment. Sampling: National Comprehensive Cancer Network (NCCN) NCCN Clinical Practice Guidelines in Oncology
More informationCharacterization of Patients with Poor-
Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationDebate: Lymphadenectomy is Important in mrcc, CON P. Mulder, M.D., Ph.D. JJ. Patard, MD, Ph.D.
Debate: Lymphadenectomy is Important in mrcc, CON P. Mulder, M.D., Ph.D. JJ. Patard, MD, Ph.D.. Eighth European International Kidney Cancer Symposium Budapest 03-04 May 2013 The role of LND In organ confined
More informationeuropean urology 52 (2007)
european urology 52 (2007) 733 745 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Systematic Assessment of the Ability of the Number and Percentage of Positive
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationGUIDELINES ON RENAL CELL CANCER
20 G. Mickisch (chairman), J. Carballido, S. Hellsten, H. Schulze, H. Mensink Eur Urol 2001;40(3):252-255 Introduction is characterised by a constant rise in incidence over the last 50 years, with a predominance
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationMultidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 20 April, Antalya, Turkey RCC European Union 60.000 new diagnoses/year 26.000 Cancer related deaths
More informationCytoreductive Nephrectomy
Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive
More informationPatient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D.
Patient Selection for Surgery in RCC with Thrombus E. Jason Abel, M.D. RCC with venous invasion Venous invasion occurs in ~10% of RCC Surgery more complex Increased risk for morbidity Thrombus may be confined
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationRenal cell cancer: overview and immunochemotherapy
1 Renal cell cancer: overview and immunochemotherapy Vincent Khoo Introduction and epidemiology Kidney cancer is a relatively common urological cancer, accounting for approximately 2% of all adult cancers.
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationLymphadenectomy in RCC: Yes, No, Clinical Trial?
Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University
More informationRadical Nephrectomy for Renal Cell Carcinoma Its Contemporary Role Related to Histologic Type, Tumor Size, and Nodal Status: A Retrospective Study
AJCP /ORIGINAL ARTICLE Radical Nephrectomy for Renal Cell Carcinoma Its Contemporary Role Related to Histologic Type, Tumor Size, and Nodal Status: A Retrospective Study Kamran M. Mirza, MD, PhD, Jerome
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationSurgeons Perspective: LN as a Draining Pattern. Jose A. Karam, MD, FACS Associate Professor Department of Urology
Surgeons Perspective: LN as a Draining Pattern Jose A. Karam, MD, FACS Associate Professor Department of Urology Disclosures EMD Serono, Pfizer, Novartis: Advisory board/consultant Disclosures I perform
More informationLymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity
EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:
More informationPrognostic Relevance of the Histological Subtype of Renal Cell Carcinoma
Clinical Urology Prognostic Relevance of the Histological Subtype of RCC International Braz J Urol Vol. 34(1): 3-8, January - February, 2008 Prognostic Relevance of the Histological Subtype of Renal Cell
More informationRole and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017
Role and extension of lymph node dissection in kidney, bladder and prostate cancer Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Bladder Cancer LN dissection in Bladder cancer 25% of patients
More informationPrincipal Investigator. General Information. Conflict of Interest Published on The YODA Project (http://yoda.yale.edu)
Principal Investigator First Name: Antonio Last Name: Finelli Degree: MD, MSc, FRCSC Primary Affiliation: Princess Margaret Cancer Centre E-mail: antonio.finelli@uhn.ca Phone number: 416-946-4501 x2851
More informationGUIDELINES ON RENAL CELL CARCINOMA
GUIDELINES ON RENAL CELL CARCINOMA B. Ljungberg (chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction This EAU guideline was prepared to help urologists
More informationAndrogen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?
Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationSurgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 23 March 2012, Sao Paulo, Brazil Surgery of RCC Locally confined (small) renal tumours Locally advanced disease Metastatic
More informationImpact of Venous Tumour Thrombus Consistency (Solid vs Friable) on Cancer-specific Survival in Patients with Renal Cell Carcinoma
EUROPEAN UROLOGY 60 (2011) 358 365 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Impact of Venous Tumour Thrombus Consistency (Solid vs Friable) on Cancer-specific
More informationUpper urinary tract urothelial carcinomas (UTUC)
Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationPredictive Models. Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute
Predictive Models Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute Treatment for clinically localized prostate cancer Trade off: Substantial
More informationA Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy
1254 A Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy Nazareno Suardi, MD 1,2 Christopher R. Porter, MD 3 Alwyn M. Reuther, MD 4 Jochen Walz, MD 1,5 Koichi Kodama, MD
More informationPatient Reported Weight Loss Predicts Recurrence Rate in Renal Cell Cancer Cases after Nephrectomy
DOI:10.22034/APJCP.2018.19.4.891 RESEARCH ARTICLE Editorial Process: Submission:01/04/2017 Acceptance:09/11/2017 Patient Reported Weight Loss Predicts Recurrence Rate in Renal Cell Cancer Cases after Nephrectomy
More informationGuidelines on Renal Cell
Guidelines on Renal Cell Carcinoma (Text update March 2009) B. Ljungberg (Chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction Renal cell carcinoma
More informationResponse Assessment Classification in Patients with Advanced Renal Cell Carcinoma Treated on Clinical Trials
1611 Response Assessment Classification in Patients with Advanced Renal Cell Carcinoma Treated on Clinical Trials Effect of Measurement Criteria and Other Parameters Lawrence H. Schwartz, M.D. 1,2 Madhu
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationCanadian Urological Association guidelines for followup of patients after treatment of nonmetastatic
Canadian Urological Association guidelines for followup of patients after treatment of nonmetastatic renal cell carcinoma Wassim Kassouf, Leonardo L. Monteiro, Darrel E. Drachenberg, Adrian S. Fairey,
More informationSystems Pathology in Prostate Cancer. Description
Section: Medicine Effective Date: July 15, 2015 Subject: Systems Pathology in Prostate Cancer Page: 1 of 8 Last Review Status/Date: June 2015 Systems Pathology in Prostate Cancer Description Systems pathology,
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma The Harvard community has made this article
More informationComparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population
DOI 10.1007/s10147-015-0812-9 ORIGINAL ARTICLE Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population Yasunobu
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationBrain Metastasis From Renal Cell Carcinoma. BACKGROUND. Patients with renal cell carcinoma brain metastases (RCCBM) are
1641 Brain Metastasis From Renal Cell Carcinoma Presentation, Recurrence, and Survival Brian Shuch, MD 1 Jeff C. La Rochelle, MD 1 Tobias Klatte, MD 1 Stephen B. Riggs, MD 1 Weiqing Liu, MS 2 Fairooz F.
More informationRadiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience
Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Poster No.: RO-0003 Congress: RANZCR FRO 2012 Type: Scientific Exhibit Authors: C. Harrington,
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationPositron emission tomography predicts survival in malignant pleural mesothelioma
Flores et al General Thoracic Surgery Positron emission tomography predicts survival in malignant pleural mesothelioma Raja M. Flores, MD, a Timothy Akhurst, MD, b Mithat Gonen, PhD, c Maureen Zakowski,
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationElsevier Editorial System(tm) for European Urology Manuscript Draft
Elsevier Editorial System(tm) for European Urology Manuscript Draft Manuscript Number: EURUROL-D-13-00306 Title: Post-Prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem Article
More informationRevisione Oral Abstracts
Revisione Oral Abstracts Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi UPDATES and NEWS from the Genitourinary Cancers Symposium - Milano,
More informationPrognostic Value of Renal Vein and Inferior Vena Cava Involvement in Renal Cell Carcinoma
european urology 55 (2009) 452 460 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Prognostic Value of Renal Vein and Inferior Vena Cava Involvement in Renal
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationVincenzo Ficarra. Direttore Clinica di Urologia Azienda Ospedaliera Universitaria di Udine
Best Papers on Kidney Cancer Vincenzo Ficarra Direttore Clinica di Urologia Azienda Ospedaliera Universitaria di Udine Uro-oncological oncological topics Renal Tumor biopsy Positive Surgical Margins after
More informationWhen to perform preoperative chest computed tomography for renal cancer staging
When to perform preoperative chest computed tomography for renal cancer staging Alessandro Larcher*, Paolo Dell Oglio*, Nicola Fossati*, Alessandro Nini*, Fabio Muttin*, Nazareno Suardi*, Francesco De
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationCorrelation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW
Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,
More informationObjectives. Patients and Methods. Conclusion. Keywords. Results. Introduction
predicts pathological nodal involvement for patients with renal cell carcinoma: development of a risk prediction model Boris Gershman*, Naoki Takahashi, Daniel M. Moreira*, Robert H. Thompson*, Stephen
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationComplex case Presentations
Complex case Presentations Case Presentations April 2016 Lisa M Pickering Case presentations: chromophobe renal carcinoma 60 year old man. ECOG PS 0 No significant comorbodities August 2009: L radical
More informationDiagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018
Diagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018 Dr. Tzahi Neuman Dep.Of Pathology Hadassah Medical Center Jerusalem, Israel, (tneuman@hadassah.org.il) Disclosure: 1 no conflicts of
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationAdjuvant Therapy in Renal Cell Carcinoma: Where Are We?
european urology supplements 6 (2007) 492 498 available at www.sciencedirect.com journal homepage: www.europeanurology.com Adjuvant Therapy in Renal Cell Carcinoma: Where Are We? Tim Eisen * University
More informationPrognostic evaluation of clear cell renal cell carcinoma
ORIGINAL ARTICLE Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment Comparisons With WHO/ISUP Grade and Integrated Staging Systems
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma
ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4
More informationNumber of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival
Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,
More informationLower Baseline PSA Predicts Greater Benefit From Sipuleucel-T
Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater
More informationDifferential lymph node retrieval in rectal cancer: associated factors and effect on survival
Original Article Differential lymph node retrieval in rectal cancer: associated factors and effect on survival Cedrek McFadden 1, Brian McKinley 1, Brian Greenwell 2, Kaylee Knuckolls 1, Patrick Culumovic
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationRecent Developments in Research on Kidney Cancer: Highlights from Urological and Oncological Congresses in 2007
european urology supplements 7 (2008) 494 507 available at www.sciencedirect.com journal homepage: www.europeanurology.com Recent Developments in Research on Kidney Cancer: Highlights from Urological and
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationREAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO
REAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO Alain Ravaud, MD.PhD Bordeaux. France DISCLOSURES Consultant for: Pfizer, Novartis, GlaxoSmithKline, Roche, Bristol-Myers Squibb Institutional
More informationAccepted for publication 12 August 2009 S.F.S. and G.G. are currently at Memorial Sloan-Kettering Cancer Center in New York, NY, USA
. JOURNAL COMPILATION 2009 BJU INTERNATIONAL Urological Oncology ASSOCIATION OF AGE WITH OUTCOMES OF UPPER TRACT UROTHELIAL CARCINOMA SHARIAT ET AL. BJUI BJU INTERNATIONAL Advanced patient age is associated
More informationRecruiting Active; not recruiting Completed Suspended Terminated. The biological sex of the patient. Female Unknown
Clinical Data Form Kidney Carcinoma Clinical Trial Sequencing Project Page 1 The Clinical Data Form (CDF) should be completed for every case. This form can be completed at the time the samples are submitted,
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More informationUK CAA Oncology Certification Charts
UK CAA Oncology Certification Charts 1. Colorectal 2. Malignant Melanoma 3. Germ Cell Tumour of Testis 4. Renal Cell Carcinoma 5. Breast Carcinoma 6. Non-small Cell Lung Cancer Note: All Class 1 cases
More information